Cynthia A. Gates - Concepedia

Author

Cynthia A. Gates

Vertex Pharmaceuticals (United States)

Also Known As

C A Gates, C GATES, C. A. GATES, C. A. Gates, C. Gates, C.A. Gates, Cynthia A Gates, Cynthia A. Gates, Cynthia Gates

Publications

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)University of Wisconsin–Madison Eli Lilly (United States)

About

Cynthia A. Gates is an author at Vertex Pharmaceuticals (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	878
2	Biochemistry	7	7	248
3	Natural Sciences	4	4	339
4	Engineering	1	1	46
5	Health Sciences	1	1	318

Cynthia A. Gates

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease Robert B. Perni, Susan J. Almquist, Randal A. Byrn, Antimicrobial Agents and Chemotherapy	2006	382
Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers Karina A. Orle, Cynthia A. Gates, David H. Martin, Journal of Clinical Microbiology Pathogen DetectionViral DiagnosticsPathologyGenital UlcersNucleic Acid Amplification Test	1996	318
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 Chao Lin, Kai Lin, Yu-Ping Luong, Journal of Biological Chemistry	2004	289
In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 Chao Lin, Cynthia A. Gates, B. Govinda Rao, Journal of Biological Chemistry Viral HepatitisNs3.4a Serine ProteaseNatural SciencesAntiviral Drug DevelopmentAntiviral Therapy	2005	216
Synthesis of 21,21-Difluoro-3β-hydroxy-20-methylpregna-5,20-diene and 5,16,20-Triene as potential inhibitors of steroid C17(20) lyase Philip M. Weintraub, Amy K. Holland, Cynthia A. Gates, Bioorganic & Medicinal Chemistry BiochemistryMedicineSteroid C17Potential InhibitorsOrganic Chemistry	2003	79
Inhibitors of hepatitis C virus NS3·4A protease 2. Warhead SAR and optimization Robert B. Perni, J. PITLIK, Shawn Britt, Bioorganic & Medicinal Chemistry Letters ImmunologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral Therapy	2004	62
Indeterminate Human Immunodeficiency Virus Type 1 Western Blots: Seroconversion Risk, Specificity of Supplemental Tests, and an Algorithm for Evaluation Connie Celum, Robert W. Coombs, William E. Lafferty, The Journal of Infectious Diseases	1991	60
Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants Robert B. Perni, Luc J. Farmer, Kevin M. Cottrell, Bioorganic & Medicinal Chemistry Letters Viral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirology	2004	52
FLP recombinase is an enzyme. Cynthia A. Gates, Michael M. Cox Proceedings of the National Academy of Sciences EngineeringFlp Protein ConcentrationCellular EnzymologyFlp MonomerNatural Sciences	1988	46
Substrate specificities and structure-activity relationships for the nucleotidylation of antibiotics catalyzed by aminoglycoside nucleotidyltransferase 2"-I Cynthia A. Gates, Dexter B. Northrop Biochemistry Thirteen Aminoglycoside AntibioticsBiochemistryAminoglycoside Nucleotidyltransferase 2Natural SciencesBiocatalysis	1988	43

Page 1